prednisolone has been researched along with Angioma in 90 studies
Prednisolone: A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.
prednisolone : A glucocorticoid that is prednisone in which the oxo group at position 11 has been reduced to the corresponding beta-hydroxy group. It is a drug metabolite of prednisone.
Angioma: A vascular anomaly due to proliferation of blood or lymphatic vessels that forms a tumor-like mass. Vessels in the angioma may or may not be dilated.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Our primary objective was to review the current use of propranolol for treatment of infantile hemangioma (IH), specifically regarding 1) the age at initiation of therapy, 2) the method of initiation, 3) the use of other adjuvant therapy, 4) the duration of therapy and relapse rate, 5) the adverse events, and 6) the outcome." | 10.25 | Status of propranolol for treatment of infantile hemangioma and description of a randomized clinical trial. ( Bauman, NM; Greene, EA; McCarter, R; Menezes, MD, 2011) |
| "There are limited data from randomized clinical trials comparing propranolol and steroid medication for treatment of infantile hemangioma (IH)." | 9.24 | Comparison of Efficacy and Safety Between Propranolol and Steroid for Infantile Hemangioma: A Randomized Clinical Trial. ( Cheon, JE; Choe, YS; Choi, TH; Choi, Y; Hong, KY; Jeong, JH; Kang, HJ; Kim, DY; Kim, KH; Lee, H; Park, JB; Park, KD; Park, YW; Shin, HY, 2017) |
| "Combining propranolol with corticosteroids gives a faster response and should be considered in treating life- or function-threatening hemangiomas." | 9.20 | Therapeutic superiority of combined propranolol with short steroids course over propranolol monotherapy in infantile hemangioma. ( Abdel Kader, HM; Aly, MM; Ghazy, MS; Hamza, AF; Ragab, IA; Saafan, HA, 2015) |
| "While propranolol is touted as superior to prednisolone for treating infantile hemangiomas (IH), a randomized clinical trial (RCT) comparing the outcome and tolerability of these medications for symptomatic, proliferating IH has not been reported." | 9.19 | Propranolol vs prednisolone for symptomatic proliferating infantile hemangiomas: a randomized clinical trial. ( Bauman, NM; Greene, EA; Guzzetta, PC; He, J; McCarter, RJ; Oh, AK; Preciado, DA; Puttgen, KB; Shin, JJ, 2014) |
| "The purpose of this study was to compare the efficacy of orally administered propranolol versus prednisolone versus both in the treatment of potentially disfiguring or functionally threatening infantile hemangiomas." | 9.17 | Effect of propranolol vs prednisolone vs propranolol with prednisolone in the management of infantile hemangioma: a randomized controlled study. ( Malik, MA; Menon, P; Rao, KL; Samujh, R, 2013) |
| " A cavernous hemangioma was suspected and treated with high doses of propranolol and prednisolone." | 7.85 | Unexpected Effect of Propranolol and Prednisolone on Infantile Facial Rhabdomyosarcoma. ( Bhandari, SB; Lemperle, G; Mentzel, T; Shakya, J; Shilpakar, R, 2017) |
| "Propranolol was first used in 2008 to treat hemangioma; its efficacy and safety have since changed the classical treatment indications." | 7.85 | A New Perspective for Infantile Hepatic Hemangioma in the Age of Propranolol: Experience at Baskent University. ( Boyvat, F; Demir, Ş; Erbay, A; Özçay, F; Sarıalioğlu, F; Uslu, N; Yazıcı, N, 2017) |
| "The aim of this study was to explore the efficacy and safety of propranolol in treating infantile haemangiomas, the most common benign vascular tumours in children." | 7.83 | Propranolol was effective in treating cutaneous infantile haemangiomas in Thai children. ( Jetsrisuparb, C; Komwilaisak, P; Panombualert, S; Techasatian, L; Uppala, R, 2016) |
| " We present a retrospective case series of 17 patients with IH who were treated with oral corticosteroid therapy and developed hypertension requiring treatment with the angiotensin converting enzyme inhibitor, captopril." | 7.78 | Effect of captopril on infantile haemangiomas: a retrospective case series. ( Christou, EM; Wargon, O, 2012) |
| "The administration of oral prednisolone using a standardized protocol of 3 mg/kg given once daily for 1 month, followed by a taper until the infant is 10 months of age, is an effective treatment for infantile hemangioma." | 7.77 | Oral prednisolone for infantile hemangioma: efficacy and safety using a standardized treatment protocol. ( Couto, RA; Greene, AK, 2011) |
| "Propranolol is an effective treatment for symptomatic IH, but its mechanism of action remains unknown and understudied." | 6.78 | Propranolol-mediated attenuation of MMP-9 excretion in infants with hemangiomas. ( Bauman, N; Brown, KJ; Movius, E; Preciado, D; Saieg, A; Thaivalappil, S, 2013) |
| "Infantile hepatic hemangioma is the most common benign liver tumor during infancy." | 6.48 | Multifocal infantile hepatic hemangiomas--imaging strategy and response to treatment after propranolol and steroids including review of the literature. ( Bosemani, T; Huisman, TA; Puttgen, KB; Tekes, A, 2012) |
| "Our primary objective was to review the current use of propranolol for treatment of infantile hemangioma (IH), specifically regarding 1) the age at initiation of therapy, 2) the method of initiation, 3) the use of other adjuvant therapy, 4) the duration of therapy and relapse rate, 5) the adverse events, and 6) the outcome." | 6.25 | Status of propranolol for treatment of infantile hemangioma and description of a randomized clinical trial. ( Bauman, NM; Greene, EA; McCarter, R; Menezes, MD, 2011) |
| "Infantile hemangiomas are the most common benign vascular tumors in childhood." | 5.56 | Propranolol-resistant infantile hemangioma successfully treated with sirolimus. ( Baselga, E; Dávila-Osorio, VL; Iznardo, H; Puig, L; Roé, E, 2020) |
| "Prior to propranolol the systemic treatment for haemangiomas was prednisolone and then the concern was the opposite, namely hypertension." | 5.42 | Propranolol and prednisolone combination for the treatment of segmental haemangioma in PHACES syndrome. ( Batul Syed, S; Gnarra, M; Harper, J; Solman, L, 2015) |
| "Haemangiomas are benign vascular tumours that generally arise in the skin during the first days of life." | 5.42 | Propranolol (Hemangiol) and severe infantile haemangiomas. The drug of first choice. ( , 2015) |
| "There are limited data from randomized clinical trials comparing propranolol and steroid medication for treatment of infantile hemangioma (IH)." | 5.24 | Comparison of Efficacy and Safety Between Propranolol and Steroid for Infantile Hemangioma: A Randomized Clinical Trial. ( Cheon, JE; Choe, YS; Choi, TH; Choi, Y; Hong, KY; Jeong, JH; Kang, HJ; Kim, DY; Kim, KH; Lee, H; Park, JB; Park, KD; Park, YW; Shin, HY, 2017) |
| "Combining propranolol with corticosteroids gives a faster response and should be considered in treating life- or function-threatening hemangiomas." | 5.20 | Therapeutic superiority of combined propranolol with short steroids course over propranolol monotherapy in infantile hemangioma. ( Abdel Kader, HM; Aly, MM; Ghazy, MS; Hamza, AF; Ragab, IA; Saafan, HA, 2015) |
| "The purpose of this study was to compare the efficacy of orally administered propranolol versus prednisolone versus both in the treatment of potentially disfiguring or functionally threatening infantile hemangiomas." | 5.17 | Effect of propranolol vs prednisolone vs propranolol with prednisolone in the management of infantile hemangioma: a randomized controlled study. ( Malik, MA; Menon, P; Rao, KL; Samujh, R, 2013) |
| " A cavernous hemangioma was suspected and treated with high doses of propranolol and prednisolone." | 3.85 | Unexpected Effect of Propranolol and Prednisolone on Infantile Facial Rhabdomyosarcoma. ( Bhandari, SB; Lemperle, G; Mentzel, T; Shakya, J; Shilpakar, R, 2017) |
| "Propranolol was first used in 2008 to treat hemangioma; its efficacy and safety have since changed the classical treatment indications." | 3.85 | A New Perspective for Infantile Hepatic Hemangioma in the Age of Propranolol: Experience at Baskent University. ( Boyvat, F; Demir, Ş; Erbay, A; Özçay, F; Sarıalioğlu, F; Uslu, N; Yazıcı, N, 2017) |
| "The aim of this study was to explore the efficacy and safety of propranolol in treating infantile haemangiomas, the most common benign vascular tumours in children." | 3.83 | Propranolol was effective in treating cutaneous infantile haemangiomas in Thai children. ( Jetsrisuparb, C; Komwilaisak, P; Panombualert, S; Techasatian, L; Uppala, R, 2016) |
| " We present a retrospective case series of 17 patients with IH who were treated with oral corticosteroid therapy and developed hypertension requiring treatment with the angiotensin converting enzyme inhibitor, captopril." | 3.78 | Effect of captopril on infantile haemangiomas: a retrospective case series. ( Christou, EM; Wargon, O, 2012) |
| "The administration of oral prednisolone using a standardized protocol of 3 mg/kg given once daily for 1 month, followed by a taper until the infant is 10 months of age, is an effective treatment for infantile hemangioma." | 3.77 | Oral prednisolone for infantile hemangioma: efficacy and safety using a standardized treatment protocol. ( Couto, RA; Greene, AK, 2011) |
| "Accelerated regression of the haemangioma was observed in four of the five patients who received intralesional triamcinolone and there was no complication." | 3.77 | Steroid therapy for problematic proliferating haemangioma. ( Aburn, NH; Leadbitter, PH; Tan, BH; Tan, ST, 2011) |
| " This case emphasizes the importance of screening for hypothyroidism in patients with hemangiomas and the potential therapeutic benefit of prednisolone therapy in this condition." | 3.74 | Case report: consumptive hypothyroidism consequent to multiple infantile hepatic haemangiomas. ( Cho, YH; Hardwick, R; Howard, NJ; Howman-Giles, R; Lord, D; Mansour, A; Taplin, C, 2008) |
| "The patient received orally administered prednisolone therapy and underwent endovascular embolization of paravertebral and spinal angiomas with the use of n-butyl-2-cyanoacrylate." | 3.72 | Cobb syndrome in an infant: treatment with endovascular embolization and corticosteroid therapy: case report. ( Iihara, K; Nagata, I; Sakai, N; Soeda, A, 2003) |
| "A 3-month-old infant was administered high-dose systemic prednisolone for management of a hemangioma of the nasal sidewall." | 3.71 | An unusual complication of the treatment of a hemangioma. ( Balfour, I; Pokorny, JJ; Rinehart, G; Roth, F, 2002) |
| "Propranolol is an effective treatment for symptomatic IH, but its mechanism of action remains unknown and understudied." | 2.78 | Propranolol-mediated attenuation of MMP-9 excretion in infants with hemangiomas. ( Bauman, N; Brown, KJ; Movius, E; Preciado, D; Saieg, A; Thaivalappil, S, 2013) |
| "Infantile hepatic hemangioma is the most common benign liver tumor during infancy." | 2.48 | Multifocal infantile hepatic hemangiomas--imaging strategy and response to treatment after propranolol and steroids including review of the literature. ( Bosemani, T; Huisman, TA; Puttgen, KB; Tekes, A, 2012) |
| "The haemangioma was not life threatening but extension within the mouth was associated with bleeding and ulceration, which was impairing feeding and speech development." | 2.42 | Vincristine as a treatment for a large haemangioma threatening vital functions. ( Fawcett, SL; Grant, I; Hall, PN; Kelsall, AW; Nicholson, JC, 2004) |
| "Tufted haemangioma is a rare, acquired vascular tumour most commonly presenting in the first year of life." | 2.39 | Tufted haemangioma responding to high-dose systemic steroids: a case report and review of the literature. ( Jackson, JE; Jones, RR; Munn, SE, 1994) |
| "The principles of treatment for hemangiomas based upon our clinical classification are discussed and may be summarized as follows: 1." | 2.36 | Vascular and lymphatic tumors in infancy, childhood and adulthood: challenge of diagnosis and treatment. ( Edgerton, MT; Hiebert, JM, 1978) |
| "Consumptive hypothyroidism is a rare paraneoplastic syndrome characterized by excessive inactivation of the thyroid hormones due to increased type 3 iodothyronine deiodinase activity of tumors." | 1.56 | A Case of Consumptive Hypothyroidism in a 1-Month-Old Boy with Diffuse Infantile Hepatic Hemangiomas. ( Hong, KT; Kim, GB; Kim, YH; Ko, JS; Lee, YA; Lee, YJ; Shin, CH, 2020) |
| "Infantile hemangiomas are the most common benign vascular tumors in childhood." | 1.56 | Propranolol-resistant infantile hemangioma successfully treated with sirolimus. ( Baselga, E; Dávila-Osorio, VL; Iznardo, H; Puig, L; Roé, E, 2020) |
| "Tufted angioma is a benign vascular proliferation which presents most commonly in infants and children and could occasionally be complicated by Kasabach-Merritt syndrome." | 1.48 | Tufted angioma arising at the site of hepatitis B vaccination: A case report. ( Hajizadeh, J; Jowkar, F; Sari-Aslani, F; Sepaskhah, M, 2018) |
| "Haemangiomas are benign vascular tumours that generally arise in the skin during the first days of life." | 1.42 | Propranolol (Hemangiol) and severe infantile haemangiomas. The drug of first choice. ( , 2015) |
| "Prior to propranolol the systemic treatment for haemangiomas was prednisolone and then the concern was the opposite, namely hypertension." | 1.42 | Propranolol and prednisolone combination for the treatment of segmental haemangioma in PHACES syndrome. ( Batul Syed, S; Gnarra, M; Harper, J; Solman, L, 2015) |
| "Large perineal hemangiomas are commonly associated with extracutaneous abnormalities." | 1.42 | Cloacal reconstruction after a complex treatment of perineal haemangioma in a variant of PELVIS syndrome. ( Posiunas, G; Raistenskis, J; Raugalas, R; Strupas, S; Verkauskas, G; Zalimas, A, 2015) |
| "Although dosing and treatment protocol is still debatable, steroids and interferon are good options for hemangioma treatment." | 1.38 | Infantile hemangiomas, complications and follow-up. ( Agaoglu, L; Akcay, A; Anak, S; Baykal, C; Devecioglu, O; Garipardic, M; Karakas, Z; Ozturk, G; Saribeyoglu, ET; Unuvar, A, 2012) |
| "Infantile hemangiomas are the most common benign tumors of infancy." | 1.36 | Immunosuppressive effects in infants treated with corticosteroids for infantile hemangiomas. ( Drolet, BA; Grossman, WJ; Juern, AM; Kelly, ME; Schauer, DW, 2010) |
| "Cogan's syndrome is a rare multisystem disorder of unknown etiology which is characterized by nonsyphilitic interstitial keratitis, vestibuloauditory dysfunction and systemic vasculitis." | 1.35 | A rare case of uneventful pregnancy in a woman with Cogan's syndrome. ( Bakalianou, K; Danilidou, K; Iavazzo, C; Kondi-Pafiti, A; Papadias, K; Salakos, N, 2008) |
| "Infants with hemangiomas are at low risk of adrenal insufficiency following the completion of GC therapy, as used in our hemangioma center." | 1.35 | Prevalence of adrenal insufficiency following systemic glucocorticoid therapy in infants with hemangiomas. ( Adams, D; Azizkhan, RG; Backeljauw, PF; Lomenick, JP; Lucky, AW; Reifschneider, KL; Woo, JG, 2009) |
| "Glomeruloid hemangioma is a specific marker of POEMS syndrome and is related to Castleman's disease." | 1.35 | Glomeruloid hemangioma. ( Shikata, N; Takasu, K; Tsubura, A; Yamazaki, F; Yuri, T, 2008) |
| "Cutaneous hemangiomas were present in four cases." | 1.34 | Infantile hepatic hemangioendothelioma: clinical presentation and treatment. ( Ozkan, TB; Sevinir, B, 2007) |
| "Sinus pericranii is a rare finding that has not, to our knowledge, been previously associated with PHACE syndrome." | 1.33 | Infantile midline facial hemangioma with agenesis of the corpus callosum and sinus pericranii: another face of the PHACE syndrome. ( Benjamin, L; Drosou, A; Linfante, I; Mallin, K; Schachner, LA; Thaller, SR; Trowers, A; Wakhloo, AK, 2006) |
| "We discuss the current available treatments for haemangiomas and highlight that treatment should be specific to each individual case." | 1.32 | Management of a large bronchial haemangioma in an infant. ( Canny, G; O'Marcaigh, A; Russell, J; Watters, K, 2003) |
| "After 11 months of treatment, the hemangioma had all but disappeared and interferon therapy was stopped." | 1.31 | [Effectiveness and dangers of interferon-alpha in the treatment of severe hemangiomas in infants]. ( Duveau, E; Enjolras, O; Giniès, JL; Grimal, I; Verret, JL, 2000) |
| "Subglottic hemangioma is a recognized cause of paediatric upper airway obstruction." | 1.31 | Systemic steroids for the management of obstructive subglottic hemangioma. ( Al-Sebeih, K; Manoukian, J, 2000) |
| "To evaluate medical treatment for hemangiomas involving the parotid area with or without other areas of involvement." | 1.30 | The response of parotid hemangiomas to the use of systemic interferon alfa-2a or corticosteroids. ( Blei, F; Deb, G; Isakoff, M, 1997) |
| "All the untreated congenital hemangiomas (n = 24) regressed by the time the infants were 14 months of age, leaving either atrophic skin or extra skin." | 1.29 | Congenital hemangioma: evidence of accelerated involution. ( Boon, LM; Enjolras, O; Mulliken, JB, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 16 (17.78) | 18.7374 |
| 1990's | 13 (14.44) | 18.2507 |
| 2000's | 28 (31.11) | 29.6817 |
| 2010's | 30 (33.33) | 24.3611 |
| 2020's | 3 (3.33) | 2.80 |
| Authors | Studies |
|---|---|
| Dávila-Osorio, VL | 1 |
| Iznardo, H | 1 |
| Roé, E | 1 |
| Puig, L | 1 |
| Baselga, E | 1 |
| Kim, YH | 1 |
| Lee, YA | 1 |
| Shin, CH | 1 |
| Hong, KT | 1 |
| Kim, GB | 1 |
| Ko, JS | 1 |
| Lee, YJ | 1 |
| Kumar, P | 1 |
| Das, A | 1 |
| Rajbansh, P | 1 |
| Shahid, R | 1 |
| Roy, R | 1 |
| Yadav, M | 1 |
| Kim, KH | 1 |
| Choi, TH | 1 |
| Choi, Y | 1 |
| Park, YW | 1 |
| Hong, KY | 1 |
| Kim, DY | 1 |
| Choe, YS | 1 |
| Lee, H | 1 |
| Cheon, JE | 1 |
| Park, JB | 1 |
| Park, KD | 1 |
| Kang, HJ | 1 |
| Shin, HY | 1 |
| Jeong, JH | 1 |
| Charny, JW | 1 |
| Moon, AT | 1 |
| Treat, JR | 1 |
| Shilpakar, R | 1 |
| Lemperle, G | 1 |
| Mentzel, T | 1 |
| Shakya, J | 1 |
| Bhandari, SB | 1 |
| Gültekin, ND | 1 |
| Yilmaz, FH | 1 |
| Altunhan, H | 1 |
| Findik, S | 1 |
| Tokgöz, H | 1 |
| Çalişkan, Ü | 1 |
| Sepaskhah, M | 1 |
| Hajizadeh, J | 1 |
| Sari-Aslani, F | 1 |
| Jowkar, F | 1 |
| Fichel, F | 1 |
| Eschard, C | 1 |
| Zachar, D | 1 |
| Munzer, M | 1 |
| Bernard, P | 1 |
| Grange, F | 1 |
| Thaivalappil, S | 1 |
| Bauman, N | 1 |
| Saieg, A | 1 |
| Movius, E | 1 |
| Brown, KJ | 1 |
| Preciado, D | 1 |
| Malik, MA | 1 |
| Menon, P | 1 |
| Rao, KL | 1 |
| Samujh, R | 1 |
| Bauman, NM | 2 |
| McCarter, RJ | 1 |
| Guzzetta, PC | 1 |
| Shin, JJ | 1 |
| Oh, AK | 1 |
| Preciado, DA | 1 |
| He, J | 1 |
| Greene, EA | 2 |
| Puttgen, KB | 3 |
| Gnarra, M | 1 |
| Solman, L | 1 |
| Harper, J | 1 |
| Batul Syed, S | 1 |
| Aly, MM | 1 |
| Hamza, AF | 1 |
| Abdel Kader, HM | 1 |
| Saafan, HA | 1 |
| Ghazy, MS | 1 |
| Ragab, IA | 1 |
| Zalimas, A | 1 |
| Posiunas, G | 1 |
| Strupas, S | 1 |
| Raugalas, R | 1 |
| Raistenskis, J | 1 |
| Verkauskas, G | 1 |
| Techasatian, L | 1 |
| Komwilaisak, P | 1 |
| Panombualert, S | 1 |
| Uppala, R | 1 |
| Jetsrisuparb, C | 1 |
| Lie, E | 1 |
| Ji, Y | 1 |
| Chen, S | 1 |
| Xiang, B | 1 |
| Xu, Z | 1 |
| Jiang, X | 1 |
| Liu, X | 1 |
| Wang, Q | 1 |
| Lu, G | 1 |
| Yang, L | 1 |
| Sarıalioğlu, F | 1 |
| Yazıcı, N | 1 |
| Erbay, A | 1 |
| Boyvat, F | 1 |
| Demir, Ş | 1 |
| Özçay, F | 1 |
| Uslu, N | 1 |
| Bakalianou, K | 1 |
| Salakos, N | 1 |
| Iavazzo, C | 1 |
| Danilidou, K | 1 |
| Papadias, K | 1 |
| Kondi-Pafiti, A | 1 |
| Lomenick, JP | 1 |
| Reifschneider, KL | 1 |
| Lucky, AW | 1 |
| Adams, D | 1 |
| Azizkhan, RG | 1 |
| Woo, JG | 1 |
| Backeljauw, PF | 1 |
| Bigorre, M | 1 |
| Van Kien, AK | 1 |
| Valette, H | 1 |
| Madan, V | 1 |
| Lloyd, IC | 1 |
| Wakefield, RM | 1 |
| Kaleem, M | 1 |
| Judge, MR | 1 |
| Ommen, LB | 1 |
| Helgestad, J | 1 |
| Gammelgaard, L | 1 |
| Thapa, R | 1 |
| Ghosh, A | 1 |
| Dhar, S | 1 |
| Truong, MT | 1 |
| Chang, KW | 1 |
| Berk, DR | 1 |
| Heerema-McKenney, A | 1 |
| Bruckner, AL | 1 |
| Kelly, ME | 1 |
| Juern, AM | 1 |
| Grossman, WJ | 1 |
| Schauer, DW | 1 |
| Drolet, BA | 2 |
| Maguiness, SM | 1 |
| Frieden, IJ | 2 |
| Tan, BH | 1 |
| Leadbitter, PH | 1 |
| Aburn, NH | 1 |
| Tan, ST | 1 |
| Greene, AK | 1 |
| Couto, RA | 1 |
| Chim, H | 1 |
| Gosain, AK | 1 |
| Menezes, MD | 1 |
| McCarter, R | 1 |
| Kuroda, T | 1 |
| Kumagai, M | 1 |
| Nosaka, S | 1 |
| Nakazawa, A | 1 |
| Takimoto, T | 1 |
| Hoshino, K | 1 |
| Bosemani, T | 1 |
| Huisman, TA | 1 |
| Tekes, A | 1 |
| Constantinides, J | 1 |
| Prowse, P | 1 |
| Gorst, C | 1 |
| Didi, MA | 1 |
| Liew, SH | 1 |
| Blei, F | 2 |
| Christou, EM | 1 |
| Wargon, O | 1 |
| Akcay, A | 1 |
| Karakas, Z | 1 |
| Saribeyoglu, ET | 1 |
| Unuvar, A | 1 |
| Baykal, C | 1 |
| Garipardic, M | 1 |
| Anak, S | 1 |
| Agaoglu, L | 1 |
| Ozturk, G | 1 |
| Devecioglu, O | 1 |
| Soeda, A | 1 |
| Sakai, N | 1 |
| Iihara, K | 1 |
| Nagata, I | 1 |
| Watters, K | 1 |
| O'Marcaigh, A | 1 |
| Canny, G | 1 |
| Russell, J | 1 |
| Wananukul, S | 2 |
| Nuchprayoon, I | 2 |
| Seksarn, P | 2 |
| Aviles, R | 1 |
| Boyce, TG | 1 |
| Thompson, DM | 1 |
| Douri, T | 1 |
| Fawcett, SL | 1 |
| Grant, I | 1 |
| Hall, PN | 1 |
| Kelsall, AW | 1 |
| Nicholson, JC | 1 |
| Drosou, A | 1 |
| Benjamin, L | 1 |
| Linfante, I | 1 |
| Mallin, K | 1 |
| Trowers, A | 1 |
| Wakhloo, AK | 1 |
| Thaller, SR | 1 |
| Schachner, LA | 1 |
| Chan, PT | 1 |
| Lee, KC | 1 |
| Chong, LY | 1 |
| Lo, KK | 1 |
| Cheung, YF | 1 |
| Voramethkul, W | 1 |
| Judd, CD | 1 |
| Chapman, PR | 1 |
| Koch, B | 1 |
| Shea, CJ | 1 |
| Maronn, ML | 1 |
| Corden, T | 1 |
| Sevinir, B | 1 |
| Ozkan, TB | 1 |
| Weibel, L | 1 |
| Hoey, S | 1 |
| Syed, S | 1 |
| Harper, JI | 1 |
| Dunaway, D | 1 |
| Abou-Rayyah, Y | 1 |
| Grantzow, R | 1 |
| Schmittenbecher, P | 1 |
| Cremer, H | 1 |
| Höger, P | 1 |
| Rössler, J | 1 |
| Hamm, H | 1 |
| Hohenleutner, U | 1 |
| Cho, YH | 1 |
| Taplin, C | 1 |
| Mansour, A | 1 |
| Howman-Giles, R | 1 |
| Hardwick, R | 1 |
| Lord, D | 1 |
| Howard, NJ | 1 |
| Aldecoa Bilbao, V | 1 |
| Viaplana Bartolí, G | 1 |
| Teodoro Marín, S | 1 |
| Perich Durán, RM | 1 |
| Yuri, T | 1 |
| Yamazaki, F | 1 |
| Takasu, K | 1 |
| Shikata, N | 1 |
| Tsubura, A | 1 |
| Hanada, T | 1 |
| Nakahara, S | 1 |
| Takita, H | 1 |
| Oshima, M | 1 |
| David, TJ | 1 |
| Evans, DI | 1 |
| Stevens, RF | 1 |
| Semenova, GS | 1 |
| Kordonets, IG | 1 |
| Gritsiuk, SN | 1 |
| Edgerton, MT | 2 |
| Zav'ialov, PV | 2 |
| Gasanov, DG | 2 |
| Alpay, K | 1 |
| Erduran, E | 1 |
| Munn, SE | 1 |
| Jackson, JE | 1 |
| Jones, RR | 1 |
| Iwanaka, T | 1 |
| Tsuchida, Y | 1 |
| Hashizume, K | 1 |
| Kawarasaki, H | 1 |
| Utsuki, T | 1 |
| Komuro, H | 1 |
| Gupta, PK | 1 |
| Sharma, DC | 1 |
| Kumawat, DC | 1 |
| Bomb, BS | 1 |
| Kulkarni, ML | 1 |
| Kumar, CS | 1 |
| George, VG | 1 |
| Farooq, K | 1 |
| Takato, T | 1 |
| Komuro, Y | 1 |
| Yonehara, Y | 1 |
| Stenninger, E | 1 |
| Schollin, J | 1 |
| Abdul-Wahab, BR | 1 |
| Olusegun, OA | 1 |
| Boon, LM | 1 |
| Enjolras, O | 2 |
| Mulliken, JB | 1 |
| Isakoff, M | 1 |
| Deb, G | 1 |
| Ono, H | 1 |
| Mawatari, H | 1 |
| Mizoguchi, N | 1 |
| Eguchi, T | 1 |
| Sakura, N | 1 |
| Walker, P | 1 |
| Cooper, D | 1 |
| MacDonald, D | 1 |
| Grimal, I | 1 |
| Duveau, E | 1 |
| Verret, JL | 1 |
| Giniès, JL | 1 |
| Kohdera, U | 1 |
| Nishimura, M | 1 |
| Higashino, H | 1 |
| Murata, T | 1 |
| Kobayashi, Y | 1 |
| Al-Sebeih, K | 1 |
| Manoukian, J | 1 |
| Pokorny, JJ | 1 |
| Roth, F | 1 |
| Balfour, I | 1 |
| Rinehart, G | 1 |
| Sugarman, JL | 1 |
| Mauro, TM | 1 |
| Robinson, D | 1 |
| Hambleton, G | 1 |
| Hiebert, JM | 1 |
| Yodono, M | 1 |
| Takiguchi, M | 1 |
| Oyama, T | 1 |
| Sutthiwan, P | 1 |
| Padalkar, JA | 1 |
| Bapat, VS | 1 |
| Phadke, MA | 1 |
| Ujjainwalla, F | 1 |
| Cook, CL | 1 |
| Sanfilippo, JS | 1 |
| Verdi, GD | 1 |
| Pietsch, JB | 1 |
| L'vov, AA | 1 |
| Deady, JP | 1 |
| Willshaw, HE | 1 |
| Ravitch, MM | 1 |
| Gebhart, W | 1 |
| Seidl, K | 1 |
| Weissenbacher, G | 1 |
| Léb, J | 1 |
| Dénes, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Safety and Efficiency of Propranolol as an Initial Treatment for Pediatric Hemangioma[NCT01908972] | Phase 4 | 34 participants (Actual) | Interventional | 2013-06-30 | Completed | ||
| Propranolol vs Prednisolone for Infant Hemangiomas-A Clinical and Molecular Study[NCT00967226] | Phase 2 | 19 participants (Actual) | Interventional | 2009-07-31 | Terminated (stopped due to Serious adverse events with prednisolone, primarily temporary growth retardation, <5th percentile.) | ||
| Natural Berry Extract Treatment of Hemangiomas[NCT04020419] | Early Phase 1 | 12 participants (Actual) | Interventional | 2020-12-01 | Terminated (stopped due to Study ending early due to program transferring to another site.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of Participants in Which, facial edema occurs, Anytime During the 16 Weeks.. (NCT01908972)
Timeframe: up to 16weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Prednisolone | 5 |
| Propranolol | 0 |
Number of Participants in Which, Glucose levels fall (to <50mg/dl), Anytime During the 16 Weeks.. (NCT01908972)
Timeframe: up to 16weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Prednisolone | 0 |
| Propranolol | 0 |
Number of Participants in which, the Heart rate fell to <70% of acceptable age related minimum post-dose with child awake, anytime during the 16 weeks Count of patients whose Heart rate fall to <70% of acceptable age related minimum post-dose with child awake (NCT01908972)
Timeframe: up to 16weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Prednisolone | 1 |
| Propranolol | 5 |
Number of Participants in Which, the Systolic blood pressure fall of >25% of baseline postdose with child awake, Anytime During the 16 Weeks.. (NCT01908972)
Timeframe: up to 16weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Prednisolone | 1 |
| Propranolol | 5 |
All symptoms associated adverse drug reaction will be checked (NCT01908972)
Timeframe: up to 16weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Prednisolone | 15 |
| Propranolol | 16 |
The primary efficacy variable was the clinical response at 16 weeks, classified as follows: when the volume did not increase or decreased by less than 25% after treatment began, we defined it as stop of progression; when the volume decreased by 25% or more compared with the original size, we defined it as regression. Both stop of progression and regressionwere defined as reaction. If the volume at the primary efficacy evaluation point was greater than the size measured when treatment started,we called it an increase. Increase was defined as a nonreaction. (NCT01908972)
Timeframe: After 16weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Prednisolone | 14 |
| Propranolol | 16 |
We checked Number of participants with Drug compliance within 16 weeks (NCT01908972)
Timeframe: After 16 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Prednisolone | 15 |
| Propranolol | 17 |
Number of Participants With Gastroesophageal reflux within 16 weeks.. (NCT01908972)
Timeframe: up to 16weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Prednisolone | 0 |
| Propranolol | 0 |
Number of Participants with Growth Retardation within 16 weeks.. (NCT01908972)
Timeframe: up to 16weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Prednisolone | 2 |
| Propranolol | 0 |
Number of participants with Reepithelialzation in 16weeks.. (NCT01908972)
Timeframe: After 16 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Prednisolone | 4 |
| Propranolol | 8 |
Number of participants whose hemangioma showed regression in 16 weeks. (NCT01908972)
Timeframe: Within 16 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Prednisolone | 9 |
| Propranolol | 13 |
size was measure the horizontal and vertical size (2-dimension) of ulceration (from baseline to 16 weeks after medication) (NCT01908972)
Timeframe: After 16 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Prednisolone | 2 |
| Propranolol | 1 |
Number of participants whose hemangioma stop proliferating in 16weeks (NCT01908972)
Timeframe: After 16 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Prednisolone | 15 |
| Propranolol | 17 |
Percent Reduction in Hemangioma Volume from Baseline (measured by MRI or Sono (from basline to 16 weeks)) (NCT01908972)
Timeframe: After 16 weeks
| Intervention | % from baseline (Mean) |
|---|---|
| Prednisolone | 46.52 |
| Propranolol | 55.87 |
Participants were observed for any change in color. The possible change in colors included change to Red/Purple/Blue/Gray/Apricot. Reported are the number of participants who experienced a change in color by the type of color (NCT01908972)
Timeframe: After 16 weeks
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Red | Purple | |
| Prednisolone | 13 | 0 |
| Propranolol | 14 | 0 |
Number of allergy/immunology AE per study arm (NCT00967226)
Timeframe: enrollment through study closeout or study withdrawal up to 9 months
| Intervention | Adverse Events (Number) |
|---|---|
| Allergy/Immunology Events Propranolol | 1 |
| Allergy/Immunology Events Prednisolone | 1 |
Number of constitutional AEs in each study arm. (NCT00967226)
Timeframe: enrollment to study close out or withdrawal up to 9 months
| Intervention | Adverse Events (Number) |
|---|---|
| Constitutional AEs Propranolol | 2 |
| Constitutional AEs Prednisolone | 3 |
A priori primary outcome was proportional change in the total surface area as measured by lesion's outer margin length x width at baseline minus the same measure at 4 months with surrogate data used at 5 months if 4 months not available. (NCT00967226)
Timeframe: 4-5 months after initiating therapy
| Intervention | mm squared (Mean) |
|---|---|
| Propranolol | 0.57 |
| Prednisolone | 0.63 |
Number of Dermatologic Adverse Events in each study arm. (NCT00967226)
Timeframe: enrollment to study close out or withdrawal up to 9 months
| Intervention | Adverse Events (Number) |
|---|---|
| Dermatologic AEs Propranolol | 2 |
| Dermatologic AEs Prednisolone | 1 |
Number of Endocrinologic AEs (of which adrenal crisis does not overlap). (NCT00967226)
Timeframe: enrollment to close out or study withdrawal up to 9 months
| Intervention | Adverse Events (Number) |
|---|---|
| Endocrine AEs Propranolol | 0 |
| Endocrinologic AEs Prednisolone | 7 |
Number of Gastrointestinal AEs in each arm (NCT00967226)
Timeframe: enrollment to study withdrawal or study close out up to 9 months
| Intervention | Adverse Events (Number) |
|---|---|
| Gastrointestinal AEs Propranolol | 6 |
| Gastrointestinal AEs Prednisolone | 6 |
Number of Growth and Development AEs in each study arm (NCT00967226)
Timeframe: enrollment to study withdrawal or close out up to 9 months
| Intervention | Adverse Events (Number) |
|---|---|
| Growth/Developoment AEs Propranolol | 0 |
| Growth/Development AEs Prednisolone | 1 |
Number of infectious AEs in each study arm (i.e. conjunctivitis, thrush, fever) (NCT00967226)
Timeframe: enrollment to study withdrawal or close out up to 9 months
| Intervention | Adverse Events (Number) |
|---|---|
| Infectious AEs Propranolol | 5 |
| Infectious AEs Prednisolone | 3 |
Number of Metabolic or Laboratory AEs in each study arm. (NCT00967226)
Timeframe: enrollment to study withdrawal or close out up to 9 months
| Intervention | Adverse Events (Number) |
|---|---|
| Metabolic/Laboratory AEs Propranolol | 1 |
| Metabolic/Laboratory AEs Prednisolone | 0 |
Number of serious adverse events experienced by the participants in each treatment arm within the categories adrenal crisis, growth/development, constitutional. Serious adverse events are defined as events that result in death, require either inpatient hospitalization or the prolongation of hospitalization, are life-threatening, result in a persistent or significant disability/incapacity, or result in a congenital anomaly/birth defect. Other important medical events, based upon appropriate medical judgment, may also be considered Serious Adverse Events if a trial participant's health is at risk and intervention is required to prevent an outcome mentioned. (NCT00967226)
Timeframe: enrollment until study close out or withdrawal up to 9 months
| Intervention | Serious Adverse Events (Number) |
|---|---|
| Number of Serious Adverse Events in Propranolol | 1 |
| Number of Serious Adverse Events in Prednisolone | 11 |
Number of pulmonary/respiratory adverse events (CTCAE 22) in each study arm (NCT00967226)
Timeframe: enrollment through study close out or withdrawal, up to 9 months
| Intervention | Adverse Events (Number) |
|---|---|
| Pulmonary/Respiratory AEs Propranolol | 14 |
| Pulmonary/Respiratory AEs Prednisolone | 4 |
Number of Vascular AEs in each study arm. (NCT00967226)
Timeframe: enrollment to study withdrawal or close out up to 9 months
| Intervention | Adverse Events (Number) |
|---|---|
| Vascular AEs Propranolol | 3 |
| Vascular AEs Prednisolone | 4 |
All adverse events relating to medication tolerability including: adrenal crisis, growth/development, constitutional (dehydration), allergy/immunology, dermatologic, endocrine, GI, infection, metabolism/labs, pulmonary, vascular. (NCT00967226)
Timeframe: enrollment until study close out or withdrawal up to 9 months
| Intervention | Events (Number) | |
|---|---|---|
| Adverse Events | Serious Adverse Events | |
| Overall Number of Adverse Events in Prednisolone | 30 | 11 |
| Overall Number of Adverse Events in Propranolol | 34 | 1 |
8 reviews available for prednisolone and Angioma
| Article | Year |
|---|---|
Current management of infantile hemangiomas.
Topics: Facial Neoplasms; Glucocorticoids; Hemangioma; Humans; Infant; Laser Therapy; Liver Neoplasms; Predn | 2010 |
Status of propranolol for treatment of infantile hemangioma and description of a randomized clinical trial.
Topics: Age Factors; Child; Child, Preschool; Hemangioma; Humans; Prednisolone; Propranolol; Recurrence; Tre | 2011 |
Multifocal infantile hepatic hemangiomas--imaging strategy and response to treatment after propranolol and steroids including review of the literature.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Female; Glucocorticoids; Heart Failure; Hema | 2012 |
Vincristine as a treatment for a large haemangioma threatening vital functions.
Topics: Antineoplastic Agents, Phytogenic; Female; Glucocorticoids; Head and Neck Neoplasms; Hemangioma; Hum | 2004 |
Tufted haemangioma responding to high-dose systemic steroids: a case report and review of the literature.
Topics: Buttocks; Drug Administration Schedule; Female; Hemangioma; Humans; Infant; Prednisolone; Skin Neopl | 1994 |
Vascular and lymphatic tumors in infancy, childhood and adulthood: challenge of diagnosis and treatment.
Topics: Adult; Angiomatosis; Arteriovenous Malformations; Blood Coagulation Disorders; Child; Female; Gigant | 1978 |
[Corticosteroid therapy of hemangiomas in children (literature survey)].
Topics: Administration, Oral; Adrenal Cortex Hormones; Age Factors; Child; Child, Preschool; Drug Evaluation | 1975 |
Capillary hemangioma of the vagina and urethra in a child: response to short-term steroid therapy.
Topics: Child, Preschool; Drug Administration Schedule; Female; Hemangioma; Hemorrhage; Humans; Prednisolone | 1989 |
7 trials available for prednisolone and Angioma
| Article | Year |
|---|---|
Comparison of Efficacy and Safety Between Propranolol and Steroid for Infantile Hemangioma: A Randomized Clinical Trial.
Topics: Female; Glucocorticoids; Hemangioma; Humans; Infant; Infant, Newborn; Magnetic Resonance Imaging; Ma | 2017 |
Propranolol-mediated attenuation of MMP-9 excretion in infants with hemangiomas.
Topics: Adrenergic beta-Antagonists; Age Factors; Antineoplastic Agents, Hormonal; Cohort Studies; Female; H | 2013 |
Effect of propranolol vs prednisolone vs propranolol with prednisolone in the management of infantile hemangioma: a randomized controlled study.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Anti-Inflammatory Agents; Drug Administration Sch | 2013 |
Propranolol vs prednisolone for symptomatic proliferating infantile hemangiomas: a randomized clinical trial.
Topics: Administration, Oral; Antineoplastic Agents, Hormonal; Female; Hemangioma; Humans; Infant; Infant, N | 2014 |
Propranolol vs prednisolone for symptomatic proliferating infantile hemangiomas: a randomized clinical trial.
Topics: Administration, Oral; Antineoplastic Agents, Hormonal; Female; Hemangioma; Humans; Infant; Infant, N | 2014 |
Propranolol vs prednisolone for symptomatic proliferating infantile hemangiomas: a randomized clinical trial.
Topics: Administration, Oral; Antineoplastic Agents, Hormonal; Female; Hemangioma; Humans; Infant; Infant, N | 2014 |
Propranolol vs prednisolone for symptomatic proliferating infantile hemangiomas: a randomized clinical trial.
Topics: Administration, Oral; Antineoplastic Agents, Hormonal; Female; Hemangioma; Humans; Infant; Infant, N | 2014 |
Therapeutic superiority of combined propranolol with short steroids course over propranolol monotherapy in infantile hemangioma.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Drug Therapy, Combination; Female; Follow-Up Stud | 2015 |
Clinical features and management of multifocal hepatic hemangiomas in children: a retrospective study.
Topics: Administration, Oral; Child, Preschool; Female; Hemangioma; Humans; Infant; Liver Neoplasms; Male; P | 2016 |
Status of propranolol for treatment of infantile hemangioma and description of a randomized clinical trial.
Topics: Age Factors; Child; Child, Preschool; Hemangioma; Humans; Prednisolone; Propranolol; Recurrence; Tre | 2011 |
76 other studies available for prednisolone and Angioma
| Article | Year |
|---|---|
Propranolol-resistant infantile hemangioma successfully treated with sirolimus.
Topics: Adrenergic beta-Antagonists; Child; Hemangioma; Hemangioma, Capillary; Humans; Infant; Prednisolone; | 2020 |
A Case of Consumptive Hypothyroidism in a 1-Month-Old Boy with Diffuse Infantile Hepatic Hemangiomas.
Topics: Adrenergic beta-Antagonists; Anti-Inflammatory Agents; Cholestasis; Drug Therapy, Combination; Heart | 2020 |
Multifocal annular tufted angiomas: Case report of dramatic response to oral prednisolone and review of therapeutic options.
Topics: Hemangioma; Humans; Prednisolone; Skin Neoplasms | 2021 |
Scalp Infantile Hemangioma Complicated by Life-Threatening Bleeding.
Topics: Adrenergic beta-Antagonists; Female; Glucocorticoids; Hemangioma; Hemorrhage; Humans; Infant; Predni | 2017 |
Unexpected Effect of Propranolol and Prednisolone on Infantile Facial Rhabdomyosarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Diagnosis, Differential; Facial Neoplasms; F | 2017 |
Coexistence of Kasabach-Merritt Syndrome and placental chorioangioma in a premature infant.
Topics: Anti-Inflammatory Agents; Comorbidity; Fatal Outcome; Female; Hemangioma; Humans; Infant, Newborn; K | 2018 |
Tufted angioma arising at the site of hepatitis B vaccination: A case report.
Topics: Adrenergic beta-Antagonists; Female; Glucocorticoids; Hemangioma; Hepatitis B Vaccines; Humans; Infa | 2018 |
[Kaposiform haemangioendothelioma associated with B-cell acute lymphoblastic leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Combined Modality Therapy | 2013 |
Propranolol and prednisolone combination for the treatment of segmental haemangioma in PHACES syndrome.
Topics: Abnormalities, Multiple; Adrenergic beta-Antagonists; Antineoplastic Agents, Hormonal; Blepharoptosi | 2015 |
Propranolol (Hemangiol) and severe infantile haemangiomas. The drug of first choice.
Topics: Adrenergic beta-Antagonists; Clinical Trials as Topic; Hemangioma; Humans; Prednisolone; Propranolol | 2015 |
Cloacal reconstruction after a complex treatment of perineal haemangioma in a variant of PELVIS syndrome.
Topics: Antineoplastic Agents, Hormonal; Anus, Imperforate; Combined Modality Therapy; Female; Genital Disea | 2015 |
Propranolol was effective in treating cutaneous infantile haemangiomas in Thai children.
Topics: Adrenergic beta-Antagonists; Anti-Inflammatory Agents; Female; Hemangioma; Humans; Infant, Newborn; | 2016 |
Corticosteroids as an adjunct to propranolol for infantile haemangiomas complicated by recalcitrant ulceration.
Topics: Administration, Oral; Chronic Disease; Drug Therapy, Combination; Glucocorticoids; Hemangioma; Human | 2017 |
A New Perspective for Infantile Hepatic Hemangioma in the Age of Propranolol: Experience at Baskent University.
Topics: Age of Onset; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Critical Pathways; Female; | 2017 |
A rare case of uneventful pregnancy in a woman with Cogan's syndrome.
Topics: Adult; Anti-Inflammatory Agents; Female; Hemangioma; Humans; Keratitis; Placenta Diseases; Prednisol | 2008 |
Prevalence of adrenal insufficiency following systemic glucocorticoid therapy in infants with hemangiomas.
Topics: Adrenal Insufficiency; Cosyntropin; Female; Glucocorticoids; Hemangioma; Humans; Hydrocortisone; Hyp | 2009 |
Beta-blocking agent for treatment of infantile hemangioma.
Topics: Acebutolol; Adrenergic beta-Antagonists; Anti-Inflammatory Agents; Hemangioma; Humans; Infant; Male; | 2009 |
PHACE syndrome.
Topics: Abnormalities, Multiple; Eyelid Neoplasms; Female; Glucocorticoids; Hemangioma; Humans; Infant; Magn | 2009 |
[Infantile haemangioma and intracranial vascular malformation].
Topics: Abnormalities, Multiple; Antineoplastic Agents, Hormonal; Carotid Artery, Internal; Eyelid Neoplasms | 2009 |
Infantile giant congenital melanocytic nevus: report of three unusual cases.
Topics: Buttocks; Child, Preschool; Female; Glucocorticoids; Hemangioma; Humans; Infant; Infant, Newborn; Ma | 2009 |
Propranolol for the treatment of a life-threatening subglottic and mediastinal infantile hemangioma.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Airway Obstruction; Antineoplastic Agents, Hormon | 2010 |
Immunosuppressive effects in infants treated with corticosteroids for infantile hemangiomas.
Topics: CD4-CD8 Ratio; Dose-Response Relationship, Drug; Female; Flow Cytometry; Follow-Up Studies; Glucocor | 2010 |
Steroid therapy for problematic proliferating haemangioma.
Topics: Administration, Oral; Female; Hemangioma; Humans; Infant; Infant, Newborn; Injections, Intralesional | 2011 |
Oral prednisolone for infantile hemangioma: efficacy and safety using a standardized treatment protocol.
Topics: Administration, Oral; Anti-Inflammatory Agents; Dose-Response Relationship, Drug; Drug Administratio | 2011 |
Discussion: Oral prednisolone for infantile hemangioma: efficacy and safety using a standardized treatment protocol.
Topics: Anti-Inflammatory Agents; Facial Neoplasms; Female; Head and Neck Neoplasms; Hemangioma; Humans; Mal | 2011 |
Critical infantile hepatic hemangioma: results of a nationwide survey by the Japanese Infantile Hepatic Hemangioma Study Group.
Topics: Adrenergic beta-Antagonists; Antineoplastic Agents; Blood Coagulation Disorders; Cardiac Output, Hig | 2011 |
Adrenal suppression following steroid treatment of infantile hemangiomas: expediting the move toward propranolol?
Topics: Adrenal Insufficiency; Glucocorticoids; Hemangioma; Humans; Infant; Prednisolone; Propranolol; Prosp | 2012 |
Oral prednisolone for infantile hemangioma: efficacy and safety using a standardized treatment protocol.
Topics: Anti-Inflammatory Agents; Facial Neoplasms; Female; Head and Neck Neoplasms; Hemangioma; Humans; Mal | 2012 |
Effect of captopril on infantile haemangiomas: a retrospective case series.
Topics: Angiotensin-Converting Enzyme Inhibitors; Captopril; Glucocorticoids; Hemangioma; Humans; Hypertensi | 2012 |
Infantile hemangiomas, complications and follow-up.
Topics: Anti-Inflammatory Agents; Child, Preschool; Female; Follow-Up Studies; Hemangioma; Humans; Infant; I | 2012 |
Cobb syndrome in an infant: treatment with endovascular embolization and corticosteroid therapy: case report.
Topics: Antineoplastic Agents, Hormonal; Embolization, Therapeutic; Female; Hemangioma; Humans; Infant; Nevu | 2003 |
Management of a large bronchial haemangioma in an infant.
Topics: Airway Obstruction; Anti-Inflammatory Agents; Bronchial Neoplasms; Bronchoscopy; Female; Hemangioma; | 2003 |
Treatment of Kasabach-Merritt syndrome: a stepwise regimen of prednisolone, dipyridamole, and interferon.
Topics: Abnormalities, Multiple; Child; Combined Modality Therapy; Dipyridamole; Drug Administration Schedul | 2003 |
Pneumocystis carinii pneumonia in a 3-month-old infant receiving high-dose corticosteroid therapy for airway hemangiomas.
Topics: Anti-Infective Agents; Female; Glucocorticoids; Head and Neck Neoplasms; Hemangioma; Humans; Infant; | 2004 |
Segmental facial hemangioma accompanied by brain anomalies: report of a case.
Topics: Arachnoid Cysts; Cerebellum; Disease Progression; Facial Neoplasms; Fatal Outcome; Female; Hemangiom | 2003 |
Infantile midline facial hemangioma with agenesis of the corpus callosum and sinus pericranii: another face of the PHACE syndrome.
Topics: Abnormalities, Multiple; Agenesis of Corpus Callosum; Embolization, Therapeutic; Facial Neoplasms; F | 2006 |
Glomeruloid haemangioma with cerebriform morphology in a patient with POEMS syndrome.
Topics: Adult; Antineoplastic Agents, Alkylating; Cyclophosphamide; Drug Therapy, Combination; Hemangioma; H | 2006 |
Diffuse Neonatal Hemangiomatosis: report of 5 cases.
Topics: Angiomatosis; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Female; Hemangioma | 2006 |
Intracranial infantile hemangiomas associated with PHACE syndrome.
Topics: Administration, Oral; Brain Neoplasms; Carotid Artery, Internal; Cerebellopontine Angle; Cerebellum; | 2007 |
Pneumocystis carinii pneumonia in infant treated with oral steroids for hemangioma.
Topics: Administration, Oral; Antineoplastic Agents, Hormonal; Facial Neoplasms; Female; Hemangioma; Humans; | 2007 |
Infantile hepatic hemangioendothelioma: clinical presentation and treatment.
Topics: Abdomen; Alanine Transaminase; Aspartate Aminotransferases; Dilatation, Pathologic; Female; Glucocor | 2007 |
Picture of the month. Diagnosis: periocular hemangioma: an eye-opening experience.
Topics: Adrenal Cortex Hormones; Eye; Female; Hemangioma; Humans; Infant; Ophthalmologic Surgical Procedures | 2007 |
Hemangiomas in infancy and childhood. S 2k Guideline of the German Society of Dermatology with the working group Pediatric Dermatology together with the German Society for Pediatric Surgery and the German Society for Pediatric Medicine.
Topics: Child; Child, Preschool; Combined Modality Therapy; Cross-Sectional Studies; Cryosurgery; Diagnosis, | 2008 |
Case report: consumptive hypothyroidism consequent to multiple infantile hepatic haemangiomas.
Topics: Developmental Disabilities; Glucocorticoids; Hemangioma; Humans; Hypothyroidism; Infant; Liver Neopl | 2008 |
[Hypertrophic myocardiopathy associated with oral corticosteroids in an infant with cutaneous hemangioma].
Topics: Administration, Oral; Cardiomyopathy, Hypertrophic; Female; Glucocorticoids; Hemangioma; Humans; Inf | 2008 |
Glomeruloid hemangioma.
Topics: Biomarkers, Tumor; Castleman Disease; Female; Hemangioma; Humans; Lymph Nodes; Middle Aged; Parotid | 2008 |
111In-labelled platelet scintigraphy in Kasabach-Merritt syndrome.
Topics: Afibrinogenemia; Blood Platelets; Female; Head and Neck Neoplasms; Hemangioma; Humans; Indium; Infan | 1984 |
Haemangioma with thrombocytopenia (Kasabach-Merritt syndrome).
Topics: Female; Hemangioma; Humans; Infant; Prednisolone; Syndrome; Thrombocytopenia | 1983 |
[Comparative evaluation of the treatment of hemangiomas of the protective apparatus of the eye in children].
Topics: Adolescent; Child; Child, Preschool; Electrocoagulation; Evaluation Studies as Topic; Eyelid Neoplas | 1983 |
Vascular hamartomas and hemangiomas: classification and treatment.
Topics: Adolescent; Embolization, Therapeutic; Facial Neoplasms; Female; Hamartoma; Hemangioma; Humans; Infa | 1982 |
[Treatment of hemangiomas in children].
Topics: Child, Preschool; Facial Neoplasms; Female; Follow-Up Studies; Hemangioma; Humans; Infant; Male; Pre | 1980 |
Successful therapy of a complicating periorbital angiomatous nevus with oral prednisolone.
Topics: Administration, Oral; Eyelid Neoplasms; Hemangioma; Humans; Infant; Male; Nevus; Orbital Neoplasms; | 1994 |
Intralesional corticosteroid injection with short-term oral prednisolone for infantile hemangiomas of the eyelid and orbit.
Topics: Administration, Oral; Adrenal Cortex Hormones; Eyelid Neoplasms; Female; Hemangioma; Humans; Infant; | 1994 |
Kasabach Merrit syndrome with verrucous haemangiomata.
Topics: Adolescent; Anemia, Hemolytic; Hemangioma; Humans; Male; Prednisolone; Skin Neoplasms; Syndrome; Thr | 1993 |
Oral steroids in the treatment of periorbital hemangioma.
Topics: Facial Neoplasms; Hemangioma; Humans; Infant; Prednisolone | 1993 |
Giant hemangioma of the parotid gland associated with Kasabach-Merritt syndrome: a case report.
Topics: Hemangioendothelioma; Hemangioma; Humans; Infant; Male; Parotid Neoplasms; Prednisolone; Syndrome; T | 1993 |
Diffuse neonatal haemangiomatosis in a newborn child.
Topics: Female; Hemangioma; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Liver N | 1993 |
Haemangioma of the vallecula causing acute upper airway obstruction in a 6 1/2 week old Nigerian infant with strawberry naevus.
Topics: Airway Obstruction; Cerebellar Neoplasms; Female; Hemangioma; Humans; Hydrocortisone; Infant; Nigeri | 1993 |
Congenital hemangioma: evidence of accelerated involution.
Topics: Antineoplastic Agents, Hormonal; Female; Fetal Diseases; Hemangioma; Humans; Infant; Infant, Newborn | 1996 |
The response of parotid hemangiomas to the use of systemic interferon alfa-2a or corticosteroids.
Topics: Antineoplastic Agents; Female; Glucocorticoids; Hemangioma; Humans; Infant; Interferon alpha-2; Inte | 1997 |
Clinical features and outcome of eight infants with intrahepatic porto-venous shunts detected in neonatal screening for galactosaemia.
Topics: Antineoplastic Agents, Hormonal; Female; Galactosemias; Hemangioma; Hepatic Veins; Humans; Infant, N | 1998 |
Subglottic haemangioma: controversies in management.
Topics: Antineoplastic Agents; Combined Modality Therapy; Female; Glucocorticoids; Hemangioma; Humans; Infan | 1999 |
[Effectiveness and dangers of interferon-alpha in the treatment of severe hemangiomas in infants].
Topics: Amblyopia; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Facial Neoplasms; Female; Follow- | 2000 |
Kasabach-Merritt syndrome in a Jehovah's Witness infant.
Topics: Antineoplastic Agents, Hormonal; Blood Transfusion; Christianity; Hemangioma; Humans; Infant, Newbor | 2000 |
Systemic steroids for the management of obstructive subglottic hemangioma.
Topics: Airway Obstruction; Anti-Inflammatory Agents; Child, Preschool; Dexamethasone; Drug Administration S | 2000 |
An unusual complication of the treatment of a hemangioma.
Topics: Antineoplastic Agents, Hormonal; Cardiomyopathy, Hypertrophic; Hemangioma; Humans; Infant; Male; Nos | 2002 |
Treatment of an ulcerated hemangioma with recombinant platelet-derived growth factor.
Topics: Administration, Topical; Anti-Infective Agents; Becaplermin; Drug Therapy, Combination; Female; Gels | 2002 |
Cutaneous and hepatic haemangiomata.
Topics: Cardiomegaly; Female; Hemangioma; Humans; Infant; Liver Neoplasms; Prednisolone; Skin Neoplasms | 1977 |
[Anesthesia for a patient with Kasabach-Merritt syndrome (author's transl)].
Topics: Anesthesia, Inhalation; Hemangioma; Humans; Infant, Newborn; Male; Prednisolone; Skin Neoplasms; Syn | 1978 |
Treatment of hemangiomas in pediatric patients with prednisolone.
Topics: Child, Preschool; Female; Hemangioma; Humans; Infant; Male; Prednisolone; Skin Neoplasms | 1976 |
Successful treatment of hepatic hemangiomas with corticosteroids.
Topics: Female; Hemangioma; Humans; Infant; Liver Neoplasms; Prednisolone; Skin Neoplasms; Steroids | 1992 |
[Rational tactics in the treatment of hemangioma in children].
Topics: Cryosurgery; Female; Hemangioma; Humans; Infant; Infant, Newborn; Male; Potassium Chloride; Predniso | 1989 |
Vascular hamartomas in childhood.
Topics: Administration, Topical; Amblyopia; Dexamethasone; Drug Therapy, Combination; Eyelid Neoplasms; Fema | 1986 |
The nonoperative treatment of surgical conditions in children.
Topics: Abdominal Muscles; Anti-Infective Agents, Local; Child; Child, Preschool; Congenital Abnormalities; | 1973 |
[Corticosteroid therapy of aggressively growing hemagiomas in infancy].
Topics: Administration, Oral; Female; Hemangioma; Humans; Infant; Prednisolone; Skin Neoplasms | 1972 |
[Successful treatment of hemangioma with prednisolone].
Topics: Child, Preschool; Female; Hemangioma; Humans; Infant; Infant, Newborn; Prednisolone | 1974 |